From 16–19 June 2025, MEDTECH BARCELONA had the privilege of participating in the BIO International Convention in Boston, one of the world’s leading events in biotechnology and life sciences. With over 20,000 attendees and more than 1,500 exhibitors from across the globe, BIO Boston offered an extraordinary opportunity to showcase MedTech’s growing international presence.
BIO’s renowned partnering platform continued to drive high-value networking, enabling strategic collaborations, investment opportunities, and technology transfer. The convention offered a dynamic forum where emerging priorities, innovations, and market shifts were actively discussed and showcased. Among the many insights gathered during the event, several key industry trends stood out:
- AI meets Biotech: Transforming drug discovery, diagnostics, and personalized medicine.
- Cell and Gene Therapies: Regulatory and clinical progress, with a focus on scalability and access.
- Health Equity & Global Access: Addressing inclusion, global health challenges, and innovation for underserved communities.
- Sustainable Biotech: Biotechnology tackling climate change, agriculture, and clean manufacturing.
- Strong international collaboration: Countries such as Canada, Japan, Israel, the UK, Switzerland, South Korea, and Spain (including Catalonia) stood out with robust delegations.
- Rising interest in emerging markets: Latin America, Africa, and Asia drew increased attention as growing regions for innovation and collaboration.

As a dynamic delegation of three team members; Teresa Sardón (Business Director), Carla Sapienza (Head of Business Development and Sales), and George (Account Manager), we proudly represented our company and its vibrant innovation community. Over the course of the event, we conducted 65 high-value meetings with biotech companies, CROs, distributors, accelerators, corporates, and research institutions. These interactions not only strengthened existing collaborations but also opened new avenues for international partnerships.
“BIO Boston has once again confirmed our company’s global standing as a leader in in-vitro kits in the ADME-TOX segment. We return with valuable contacts, shared projects, and renewed energy to continue building bridges between talent, technology, and health,” said Carla Sapienza.

MEDTECH BARCELONA’s participation in the BIO International Convention 2025 marked a significant step forward in strengthening its international positioning, consolidating our role as a leading hub in biotechnology and innovation, and further enhancing our global visibility. Strategic engagements allowed us to reinforce relationships with key stakeholders across North America and Europe, while identifying promising collaboration opportunities in areas such as ADME-TOX/DMPK, cell therapy, and artificial intelligence applied to health.